RECURRENT GENITAL HERPES SIMPLEX TYPE 2
Clinical trials for RECURRENT GENITAL HERPES SIMPLEX TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GENITAL HERPES SIMPLEX TYPE 2 trials appear
Sign up with your email to follow new studies for RECURRENT GENITAL HERPES SIMPLEX TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New herpes drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called ABI-5366 in 115 people to see if it is safe and how the body processes it. The trial included healthy volunteers and people with recurrent genital herpes caused by HSV-2. The goal was to gather safety data and understand dosing, not…
Matched conditions: RECURRENT GENITAL HERPES SIMPLEX TYPE 2
Phase: PHASE1 • Sponsor: Assembly Biosciences • Aim: Disease control
Last updated May 17, 2026 16:06 UTC
-
New herpes drug ABI-1179 passes first safety check in small study
Symptom relief CompletedThis early-stage study tested a new drug called ABI-1179 in 103 people. First, healthy volunteers received a single dose to check safety. Then, people with recurrent genital herpes (caused by HSV-2) received multiple doses. The main goal was to see if the drug is safe and how the…
Matched conditions: RECURRENT GENITAL HERPES SIMPLEX TYPE 2
Phase: PHASE1 • Sponsor: Assembly Biosciences • Aim: Symptom relief
Last updated May 15, 2026 11:56 UTC